Al's Comment:

 Finally some good news for a change! Although this is early data from a small noncontrolled trial, the survival times are impressive!  They just about doubled the historical average survival for recurrent GBM without serious side effects!

---

Posted on: 09/25/2019

Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress

 

---

Click HERE to return to brain tumor news headlines.